In a deal aimed at slashing the US giant's tax bill, Shire Pharmaceuticals has accepted a £32-billion ($54-billion, 40-billion-euro) takeover bid from AbbVie, the two companies announced on Friday.
The takeover, priced with a 53.0-percent premium for Shire stock, comes after Shire, based in Ireland, reversed its opposition to a deal earlier this week.
Stricter Pharmaceutical Patents Could Reduce Access to Affordable Drugs for the Poor
The American government's plans to adopt stricter pharmaceutical patents at the ongoing talks on a Pacific trade pact could reduce poor people's access to affordable drugs.
Advertisement
"The boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie," the two firms said in a statement.
The offer, comprising £24.44 in cash and 0.8960 AbbVie share per Shire share, is the same as the proposal received by the group last Sunday.
The companies added that the bid was worth the equivalent of £53.19 per Shire share, which represents a premium of 53 percent to the closing share price on May 2, one day before AbbVie's initial proposal.
![Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy]( "Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy")
A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy.
The deal was expected to reduce AbbVie's effective tax rate to about 13 percent by 2016, according to the statement.
In late morning London deals, Shire's share price jumped 2.21 percent to £49.12 on the capital's FTSE 100 index, which was down 0.61 percent.
AbbVie stressed that it will "maintain a strong commitment" to growing the shareholder dividend and implementing a "significant" share repurchase scheme.
Shire Pharmaceuticals, which is listed in London and New York but based in Dublin, is a specialist in drugs for the treatment of attention-deficit disorder and rare diseases.
"The transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease and multiple emerging oncology programs," the statement added.
Shire shareholders will own approximately 25 percent of the combined company following completion of the takeover.
Shire, which provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas, had previously rejected offers from AbbVie as undervaluing the company.
The group had also previously highlighted concerns over AbbVie's plans to make Britain its home base for tax purposes.
Source: AFP
The companies added that the bid was worth the equivalent of £53.19 per Shire share, which represents a premium of 53 percent to the closing share price on May 2, one day before AbbVie's initial proposal.
Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy
A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy.
Advertisement
The deal was expected to reduce AbbVie's effective tax rate to about 13 percent by 2016, according to the statement.
In late morning London deals, Shire's share price jumped 2.21 percent to £49.12 on the capital's FTSE 100 index, which was down 0.61 percent.
AbbVie stressed that it will "maintain a strong commitment" to growing the shareholder dividend and implementing a "significant" share repurchase scheme.
Shire Pharmaceuticals, which is listed in London and New York but based in Dublin, is a specialist in drugs for the treatment of attention-deficit disorder and rare diseases.
"The transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease and multiple emerging oncology programs," the statement added.
Shire shareholders will own approximately 25 percent of the combined company following completion of the takeover.
Shire, which provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas, had previously rejected offers from AbbVie as undervaluing the company.
The group had also previously highlighted concerns over AbbVie's plans to make Britain its home base for tax purposes.
Source: AFP
Japanese Pharmaceutical Company Starts Down's Therapy Test
A pharmaceutical company in Japan said it will begin therapeutic testing of a drug it hopes will slow the decline in quality of life for some people with Down's syndrome.
Advertisement
 Pharmaceutical Companies Delay Drug Access, Not Processing TimeThe pharmaceutical company submissions to Health Canada is delaying the access to new prescription drugs rather than delay by a longer approval-processing time, says a study. | Advertisement
|
Advertisement
Latest Lifestyle and Wellness News
Significance of sunscreen as an essential element of skincare has experienced a significant upswing in popularity due to the deleterious effects of UV rays.
Impact of workplace burnout on employee performance, wellbeing, and organizational productivity is extensive, yet the role of personal relationships has been overlooked.
Ayurveda offers a time-tested treatment for aging skin using natural herbs and antiquated traditions that value sustainability and might do wonders for skin health.
Researchers identified two key physiological systems involved in hypertension, cognitive, and emotional impairments following high salt intake.
Decoding the secrets of wrinkles by knowing the causes, prevention, and expert advice.